Reed Elsevier Annual Reports and Financial Statements 2007 19 Operating and financial review Divisional summary % change at 2007 2006 % constant m m change currencies Continuing Operations Revenue Elsevier 1,507 1,521 1% 4% LexisNexis 1,594 1,570 2% 8% Reed Business 1,483 1,418 5% 7% Total 4,584 4,509 2% 6% Adjusted operating profit Elsevier 477 465 3% 9% LexisNexis 406 380 7% 14% Reed Business 260 241 8% 10% Unallocated items 6 5 Total 1,137 1,081 5% 11% Discontinued Operations Revenue 752 889 Adjusted operating profit 121 129 Adjusted figures and constant currency movements in the following commentary growth rates are used by Reed Elsevier as refer to performance at constant exchange additional performance measures.
Underlying growth rates are operating profit is stated before the calculated at constant currencies, amortisation of acquired intangible assets excluding acquisitions and disposals.
Constant currency growth rates are based on 2006 full The reported operating profit figures are set year average and hedge exchange rates.
out in note 1 to the combined financial information and reconciled to the adjusted Unless otherwise indicated, all percentage figures in note 11.
Forward looking statements The Reed Elsevier Annual Reports and Financial Statements 2007 contain forward looking statements within the meaning of Section 27A of the US Securities Act 1933, as amended, and Section 21E of the US Securities Exchange Act 1934, as amended.
These statements are subject to a number of risks and uncertainties and actual results and events could differ materially from those currently being anticipated as reflected in such forward looking statements.
The terms expect, should be, will be and similar expressions identify forward looking statements.
Factors which may cause future outcomes to differ from those foreseen in forward looking statements include, but are not limited to: general economic conditions in Reed Elseviers markets: exchange rate fluctuations: customers acceptance of our products and services: the actions of competitors: legislative, fiscal and regulatory developments: changes in law and legal interpretations affecting Reed Elseviers intellectual property rights and internet communications: the impact of technological change: the failure to obtain regulatory approval for the acquisition of ChoicePoint Inc. or the approval of its shareholders for the proposed merger.
Operating and financial review 20 Operating and financial review continued Elsevier Elsevier had a very successful year with good underlying growth driven by new publishing and continued expansion of our online information and workflow solutions % Revenue m change at 1,521 2007 2006 % constant 1,507 m m change currencies Revenue Science & Technology 774 792 2% 2% Health Sciences 733 729 1% 6% 4% at constant currencies Total 1,507 1,521 1% 4% Adjusted operating profit 477 465 3% 9% 6% 06 07 underlying Adjusted operating margin 31.7% 30.6% 1.1pts 1.4pts Revenues and adjusted operating quality, increased for 65% of our profits were up 6% and 10% journals, more than for any other major respectively at constant currencies science and medical publisher.
Good before acquisitions and disposals.
progress was also made in our customer Adjusted operating profit m After portfolio effects, most notably the service programmes with positive 477 acquisition of the Beilstein chemical developments across a wide range of 465 compounds database and the sale of surveyed measures.
the MDL software business, revenues were up 4% and adjusted operating In March, we acquired the full rights profits up 9% at constant currencies.
to the Beilstein chemical compounds 9% at constant currencies The overall adjusted operating margin database, previously operated under improved by 1.1 percentage points, licence, which is now being integrated driven by revenue growth and cost with other resources to deliver content 10% 06 07 underlying efficiency most particularly in rich and innovative online solutions.
In October we sold the MDL software services business which increasingly The Science & Technology business saw did not fit within Elseviers strategy.
underlying revenue growth of 6%, or 2% at constant currencies after acquisitions In Health Sciences, revenue growth at and disposals, reflecting journal constant currencies was 6%, both before subscription renewals at record levels and after the impact of acquisitions and and growing online sales with increasing disposals, driven by good growth in the market penetration.
ScienceDirect saw nursing and allied health professional widening distribution especially in small sector, and expanding online solutions.
academic and emerging markets, and The year saw successful publishing and particular success from the further a growing appetite within the healthcare launch of electronic books.
industry for technology enabled information solutions to improve the ScienceDirect online usage was again up quality and effectiveness of diagnosis, over 20%.
Impact Factors, one of the treatment and care.
Growth was partly industrys standard measures of content held back by a flat performance in
